Report of the annual General Meeting of 30 May 2023

Report of the annual General Meeting of 30 May 2023
Nomination of Florence Dupré as a member of the Board of Directors

Dijon, France, 30 May 2023 at 06:00pm CEST – Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, today announced the results of its annual General Meeting, which took place at 2:30pm on 30 May 2023, and the nomination of Florence Dupré as a member of its Board of Directors.